Merck Healthcare KGaA, Darmstadt, Germany
Clinical trials sponsored by Merck Healthcare KGaA, Darmstadt, Germany, explained in plain language.
A healthcare division of Merck KGaA, a global science and technology company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced colorectal cancer: targeted drug M9140 enters early trial Results expected Sep 2026 (estimated)
- New drug M5542 tested in humans for first time Results expected Nov 2026 (estimated)
-
New hope for advanced colorectal cancer: targeted drug M9140 enters early trial
Disease control OngoingThis early-phase study tests an experimental drug called M9140 in 12 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that carry a specific marker…
Phase 1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New lupus drug enpatoran tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…
Phase 2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can we predict who will benefit from cladribine? new study aims to find out
Knowledge-focused OngoingThis observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to h…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC